Included in the 2020 National Comprehensive Cancer Network (NCCN) Guidelines for Prostate Cancer Early Detection.
SelectMDx Helps Physicians Determine if a Patient is at Higher or Lower Risk for Prostate Cancer and Which Men Can Safely Avoid Biopsy
A non-invasive urine test (“liquid biopsy”), SelectMDx measures the expression of two mRNA cancer-related biomarkers (HOXC6 and DLX1).1 The test provides binary results that, when combined with the patient’s clinical risk factors, help the physician determine whether:
- The patient may benefit from a biopsy and early prostate detection, or
- The patient can avoid a biopsy and return to routine screening
Overcomes Historical Prostate Cancer Screening Challenges for More Effective and Efficient Diagnosis
Continue to read latest press release.
Page 1 of 4